Entero Therapeutics, Inc. Total Liabilities
Entero Therapeutics, Inc. total liabilities. Based on the latest financial reports, Entero Therapeutics, Inc. (ENTO) has total liabilities worth $45.81 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ENTO asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Entero Therapeutics, Inc. (2013–2024)
Total liabilities of Entero Therapeutics, Inc. from 2013 to 2024. This chart illustrates how Entero Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Entero Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Entero Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titan Logix Corp.
V:TLA
|
Canada | CA$1.01 Million |
|
ERG S.A.
WAR:ERG
|
Poland | zł28.53 Million |
|
CoinSmart Financial Inc
NEO:SMRT
|
Canada | CA$61.00 Million |
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
USA | $1.13 Million |
|
T.M.C. Industrial Public Company Limited
BK:TMC
|
Thailand | ฿122.14 Million |
|
Emerge Commerce Ltd
V:ECOM
|
Canada | CA$18.71 Million |
|
Guardian Exploration Inc
V:GX
|
Canada | CA$2.09 Million |
|
Gullewa Ltd
AU:GUL
|
Australia | AU$1.15 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Entero Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ENTO asset base.
Liquidity & Leverage Metrics
Entero Therapeutics, Inc. Total Liabilities Ratios Explained
Entero Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entero Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entero Therapeutics, Inc. (2013–2024)
The table below shows the annual total liabilities of Entero Therapeutics, Inc. from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $27.61 Million | +741.55% |
| 2023-12-31 | $3.28 Million | +21.60% |
| 2022-12-31 | $2.70 Million | -86.25% |
| 2021-12-31 | $19.61 Million | +26.00% |
| 2020-12-31 | $15.56 Million | +263.18% |
| 2019-12-31 | $4.29 Million | +43.07% |
| 2018-12-31 | $3.00 Million | -21.56% |
| 2017-12-31 | $3.82 Million | +7.86% |
| 2016-12-31 | $3.54 Million | -65.67% |
| 2015-12-31 | $10.32 Million | +162.42% |
| 2014-12-31 | $3.93 Million | +418387.70% |
| 2013-12-31 | $939.30 | -- |
About Entero Therapeutics, Inc.
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more